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C-reactive protein (CRP) is a sensitive biomarker of chronic low-grade inflammation and is associated with multiple complex diseases.
The genetic determinants of chronic inflammation remain largely unknown, and the causal role of CRP in several clinical outcomes is
debated. We performed two genome-wide association studies (GWASs), on HapMap and 1000 Genomes imputed data, of circulating
amounts of CRP by using data from 88 studies comprising 204,402 European individuals. Additionally, we performed in silico functional
analyses and Mendelian randomization analyses with several clinical outcomes. The GWAS meta-analyses of CRP revealed 58 distinct
genetic loci (p < 5 3 108). After adjustment for body mass index in the regression analysis, the associations at all except three loci re-
mained. The lead variants at the distinct loci explained up to 7.0% of the variance in circulating amounts of CRP. We identified 66 gene
sets that were organized in two substantially correlated clusters, one mainly composed of immune pathways and the other characterized
by metabolic pathways in the liver. Mendelian randomization analyses revealed a causal protective effect of CRP on schizophrenia and a
risk-increasing effect on bipolar disorder. Our findings provide further insights into the biology of inflammation and could lead to in-
terventions for treating inflammation and its clinical consequences.Introduction
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Abbas Dehghan,1,181,* and Behrooz Z. Alizadeh2,*Unraveling the genetics of inflammation could provide
further insights into the underlying biology of inflamma-
tion and could identify therapeutic targets for attenuating
inflammation.
The genetic determinants of CRP have only been partly
characterized. In 2011, our group published a HapMap-
based genome-wide association study (GWAS) meta-anal-
ysis including a discovery panel of up to 65,000 individuals
and found 18 loci that were associated with amounts of
CRP.9 Increasing GWAS sample size and denser mapping
of the genome with further advanced imputation panels
could help to identify further genes associated with the
phenotypes of interest.10,11 Furthermore, by using genetic
instrumental variables (i.e., a genetic score), Mendelian
randomization (MR) allows investigation of the potential
causal effect of an exposure on clinical outcomes and could
help to elucidate the causal pathways that link the expo-
sure with the outcome.12 The causal role of CRP in the
development of diseases is still controversial,13 and the
causal pathways that link inflammation to complex disor-
ders are only partly understood.
Weapplied two large-scaleGWASsoncirculatory amounts
ofCRPbyusingHapMapand1000Genomes (1KG) imputed
data to identify genetic determinants of chronic inflamma-
tion. Because bodymass index (BMI) is amajor determinant
of CRP amounts, we additionally conducted a GWAS
adjusted for BMI to identify associated loci independent of
BMI. To identify any sex differences in genetic determinants
of chronic inflammation, we further conducted GWASs in
men and women separately. We applied in silico functional
analyses on the identified loci to obtain better insights
into the biological processes potentially regulating chronic
inflammation. Finally, we conducted MR analyses to pro-
vide an improved understanding of the causal relation be-
tween CRP and several related clinical outcomes.Material and Methods
GWAS for Circulating Amounts of CRP
We conducted a meta-analysis of GWASs including individuals of
Europeanancestrywithin theCohorts forHeart andAgingResearch
in Genomic Epidemiology (CHARGE) Inflammation Working
Group (CIWG).14 All participating studies were approved by an
institutional review board (see details in the Supplemental Data).
The CIWG invited cohorts for participation in the HapMap GWAS
meta-analysis of CRP amounts in 2012. In 2014, in light of our
assessment that showed complementary values of HapMap andTX 77030, USA; 226Human Genome Sequencing Center, Baylor College of Med
ogy, University of Minnesota, Minneapolis, MN 55455, USA; 228Institute of S
229National Heart, Lung, and Blood Institute’s Framingham Heart Study, Fram
School of Public Health, Boston, MA 02118, USA
231Deceased
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The American1KG imputed GWASs,10 we invited studies to participate in the
1KG GWAS meta-analysis. The 1KG GWAS could help to identify
loci that were not covered in the HapMap GWAS and fine-map
loci found in the HapMap GWAS. Cohorts were allowed to partici-
pate in either the HapMap or 1KGGWAS or both. Here, we present
a meta-analysis of both HapMap (204,402 individuals from 78
studies) and1KG (148,164 individuals from49 studies) imputed-ge-
notype GWASs. All participating cohorts implemented a pre-speci-
fied study plan comprising study design, data quality check, data
analysis, and data sharing. Wemeasured serum CRP inmg/L by us-
ing standard laboratory techniques (Supplemental Data) and trans-
formed the values by natural log. Individuals with auto-immune
diseases, individuals taking immune-modulating agents (if this in-
formation was available), and individuals with CRP amounts 4 SD
or more away from the mean were excluded from all analyses. The
characteristics of the participants are presented in Table S1. We
filtered individuals and genetic variants on the basis of study-spe-
cific quality-control criteria (Table S2). At each individual study
site, we tested genetic variants for association with amounts of
CRP by using an additive linear regression model adjusted for age,
sex, and population substructure and accounting for relatedness,
if relevant. Before meta-analysis, we filtered variants on the basis
of imputationquality at anR2 index>0.4.Toavoid type I error infla-
tion, we corrected study-specific GWASs for genomic inflation. For
the HapMap study, we conducted fixed-effect meta-analyses for
each genetic variant by using the inverse-variance-weighted
(IVW)method implemented inGWAMA15 andperformed a second
genomic control on the meta-analysis level. For the 1KG imputed
GWAS, we used METAL16 to perform a fixed-effect meta-analysis.
We removed variants that were available in only<50% of the sam-
ples. The HapMap meta-analysis included 2,437,193 variants, and
the 1KG GWAS included 10,019,203 variants. We considered asso-
ciations with p < 5 3 108 to be genome-wide significant. We
used a stringent distance criterion—aminimum of 500 kb between
two significant variants—to identify distinct loci. In each locus, the
variant with the smallest p value was called the lead variant.
Additionally, we performed sex-stratified analyses among HapMap
imputed studies, and we tested for heterogeneity between sex-spe-
cific effect estimates as described previously17 by using the false-dis-
covery rate (FDR) of Benjamini-Hochberg to assess significance of
the p value for sex difference (<0.05). We conducted BMI-adjusted
analyses in the 1KG meta-analysis to determine the role of BMI in
mediating the genetic associations with CRP and to increase power
to detect associations not mediated by BMI.
LD Score Regression
Because population stratification is a major concern in GWASs and
can lead to false-positive associations, we applied linkage disequi-
librium (LD) score regression (LDSC) to distinguish whether the
inflation of test statistics observed in the CRP GWAS was due to
the polygenic architecture of CRP or reflected confounding biasicine, Houston, TX 77030, USA; 227Department of Lab Medicine and Pathol-
ocial and Preventive Medicine, University of Bern, 3012 Bern, Switzerland;
ingham, MA 01702, USA; 230Department of Biostatistics, Boston University
Z.A.)
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due to cryptic relatedness or population stratification. The LD score
measures collective genetic variation acquired from all genetic var-
iants in LD with the index tagging (causal) variant.18 A higher LD
score of an index variant implicates more nearby genetic variants
in high LD with the index variant, which makes it more likely
that the index variant tags causal variant(s). More genetic variants
in LD with the index genetic variant (i.e., a higher LD score due to
polygenicity) could yield higher (i.e., inflated) test statistics. In
contrast, higher test statistics caused by cryptic population stratifi-
cation will not be related to the LD score. LDSC analysis performs
regression of the summary statistics from the GWASmeta-analysis
(c2 statistics from the GWAS) on the LD scores across the genome.
An LDSC intercept that equals 1 suggests no confounding bias,
whereas an inflated intercept (larger than 1) suggests contribution
of confounding due to relatedness to the test statistics.We used the
LDHubweb interface to performLDSC.19Wefilteredvariants to the
subset ofHapMap3 variants and excluded variantswith duplicated
rs numbers, ambiguous variants, minor allele frequency (MAF) <
0.01, and reported sample size < 66.7% of the total sample size.
We used the default European LD score file based on the European
1KG reference panel.
Furthermore, we applied cross-trait LDSC to estimate genetic
correlation of chronic inflammation (by using the HapMap
GWAS meta-analysis) with other phenotypes by using published
GWAS summary statistics.20 In brief, the cross-product of
two GWAS test statistics is calculated at each genetic variant,
and this cross-product is regressed on the LD score. The slope of
the regression is used for estimating the genetic covariance be-
tween two phenotypes.Identification of Additional Distinct Variants in
Associated Loci
To identify additional distinct variants in the associated loci, we
performed joint approximate conditional analysis with the 1KG
meta-analysis summary statistics and the LD matrix derived
from the first cohort of the Rotterdam Study (RS-I) (n ¼ 5,974).
We used the Genome-wide Complex Trait Analysis (GCTA) tool,
which performs a genome-wide stepwise procedure to identify var-
iants according to their distinct association with CRP (i.e., condi-
tional p).21,22 We only used variants with an imputation quality of
R2 > 0.8 in the reference set (RS-I). This approximate conditional
analysis could reveal different lead signals in a locus where multi-
ple associated variants were in the final joint association model.
We tested the distinct variants identified in CRP jointly for an as-
sociation with CRP by using individual-level data from the second
and third cohorts of the Rotterdam Study (RS-II and RS-III, totaling
5,024 subjects) and the Women’s Genome Health Study (WGHS)
of 16,299 individuals.Proportion of CRP Variance Explained
We estimated the variance explained in serum amounts of CRP by
using the formula (23MAF(1 MAF)b2)/var(CRP), where b is the
estimated effect of the individual variants on CRP23 and var(CRP)
is the estimated variance in natural-log-transformed CRP in the
RS-I cohort. We calculated the variance explained for four combi-
nations of associated variants: (1) the lead variant at just the CRP
locus, (2) the distinct variants derived from the 1KG joint condi-
tional analysis at the CRP locus, (3) all lead variants in the distinct
loci, and (4) all lead variants in the distinct loci and, when appli-
cable, the distinct variants derived from the approximate joint
conditional analysis at associated loci.696 The American Journal of Human Genetics 103, 691–706, NovemPathway Analysis and Gene Expression
We used Data-Driven Expression-Prioritized Integration for Com-
plex Traits24 (DEPICT v.1 rel173 beta) to systematically prioritize
the most likely causal genes, highlight the pathways enriched
with these genes, and identify tissues and cell types in which genes
from associated loci are highly expressed. DEPICT requires sum-
mary statistics from the GWAS meta-analysis. First, we filtered
genome-wide-associated variants from both GWAS meta-analyses
by MAF > 0.01 and selected variants with a low correlation with
other variants according to PLINK (v.1.90) by using a clumping dis-
tance of 500 kb between variants and/or index of LD r2 threshold<
0.1. The settings for the analysis involved the usage of 1KG pilot
phase data25 (phase 1 integrated release v.3; unrelated CEU [Utah
residents with ancestry from northern and western Europe], GBR
[British in England and Scotland], and TSI [Toscani in Italia] indi-
viduals;November 23, 2010)with an r2>0.5 LD threshold for locus
definition, 10,000 permutations for bias correction, and 500 repe-
titions for FDR calculation. To summarize and visualize the results,
we calculated pairwise Pearson correlation coefficients between all
gene-specific Z scores for every pair of reconstituted DEPICT gene
sets.Weused Affinity PropagationClustering (apcluster command;
APCluster R package26) to identify clusters and representative ex-
amples of the clusters and used Cytoscape v.3.2.1 to visualize the
results. The DEPICT results of the pathway and gene prioritization
are summarized as a heatmap (R v.2.3.3; pheatmap v.1.0.8 pack-
age27). The gene-specific Z score describes the likelihood that a
given gene is part of the corresponding Gene Ontology (GO)
term, KEGG pathway, REACTOME pathway, Mouse Phenotype,
or protein-protein interaction network.
Also, we performed Multi-marker Analysis of GenoMic Annota-
tion (MAGMA).28 MAGMA performs gene and gene-set analysis
and requires the association results of all variants; therefore, we
chose the larger HapMap GWAS for MAGMA. We used the Func-
tional Mapping and Annotation (FUMA)29 tool to perform
MAGMA and applied standard settings for running MAGMA.
To prioritize the most likely trait-relevant gene for each GWAS
locus, we ran colocalization analysis with the ‘‘coloc’’ R package
v.3.130 separately for the HapMap and 1KG GWASs. We used pub-
licly available genome-wide expression quantitative trait locus
(eQTL) data from 5,311 whole-blood samples31 and from the
Genome Tissue Expression (GTEx) V6p portal, which incorporates
eQTL data from 44 post-mortem tissues.32 The coloc package uses
approximate Bayes factors to estimate the posterior probability
that GWAS and eQTL effects share a single causal variant. All sig-
nificant cis-eGenes or cis-eProbes (q < 0.05 in GTEx; lowest cis-
eQTL FDR < 0.05 in Westra et al.31) were extracted5 1 Mb from
the lead SNP of each locus. The HapMap SNP positions were con-
verted to hg19 positions (UCSC Genome Browser) with the lift-
Over command from the rtracklayer v.1.38.3 package. We used
the SNPs present in both the GWAS and eQTL datasets. For the
HapMap GWAS, the 1KG GWAS, and the GTEx eQTL datasets,
we performed the test by using association b, standard error of b,
and MAF. For the data from Westra et al.,31 we used association
p value, MAF, and sample size and included only the subset of
cis-eQTLs that are publicly available (up to a significance FDR <
0.5). We used default priors supplied by the coloc package (P1 ¼
1 3 104, P2 ¼ 1 3 104, and P12 ¼ 1 3 105; prior probabilities
for association in the GWAS datasets, the eQTL datasets, and
both). Full MAF data were not available for the eQTL datasets, so
we used the GIANT 1KG p1v3 EUR reference panel instead. We
visualized the results as a heatmap by using the pheatmap
v.1.0.8 R package.27ber 1, 2018
Mendelian Randomization
To assess the effect of CRP on complex disorders, we performed a
two-sample MR study on nine clinical outcomes—Alzheimer dis-
ease (AD), bipolar disorder (BD), coronary artery disease (CAD),
Crohn disease (CD), inflammatory bowel disease (IBD), rheuma-
toid arthritis (RA), schizophrenia, and diastolic blood pressure
(DBP), and systolic blood pressure (SBP)—to which CRP showed
a potentially causal association at a p < 0.1 in a previous MR
study.13 We used the effect estimates of the 48 lead SNPs found
to be associated with CRP in the HapMap GWAS and the effect es-
timates of the four SNPs that were additionally found to be associ-
ated with CRP in the 1KG GWAS in a multiple-instrument
approach for theMR analyses (n¼ 52 SNPs). Additionally, we sepa-
rately studied the effect of rs2794520 at the CRP locus to minimize
the probability of introducing horizontal pleiotropy.We tested the
statistical significance of the association between the instrument
and CRP with the following formula:
F ¼ R
2ðn 1 kÞ
ð1 R2Þ3 k
R2 is the CRP variance explained by the genetic instrument
(0.014 for the rs2794520 SNP and 0.065 for the 52-SNP score), n
is the number of individuals included in the CRP GWAS, and k
is the number of variants included in the genetic score. The F sta-
tistic was 273 for the 52-SNP score and 2,902 for the rs2794520
SNP, indicating that both instruments were strong.
For the clinical outcomes, we used summary statistics from the
most recent meta-analysis of GWASs. For DBP and SBP, we used
data from the UK Biobank. The details of the outcome studies are
summarized in Table S12.We implemented four differentmethods
of MR analyses: the IVW method, MR-Egger, weighted median
(WM), and penalized weighted median (PWM). We used the Two-
SampleMR package in R for the MR analyses.33 Further, we applied
the Bonferroni method to correct for multiple testing (0.05/9 phe-
notypes ¼ 5.6 3 103). When the Q statistic of the IVW analyses
provided evidence for heterogeneity, the WM estimates were used
for significance. The MR methods are described briefly below.
Inverse-Variance Weighted
The IVWmethod obtains the causal estimate by regressing the SNP
associationswith the outcome on the SNP associations with the risk
factor; the intercept is set to 0, andweights are the inverse variances
(IVs)of theSNPassociationswith theoutcome.Witha single genetic
variant, the estimate is the ratio of coefficients bY/bX, and the stan-
dard error is the first term of the Dmethod approximation bYse/bX.
When all CRP SNPs are valid IVs, the IVWestimates converge to the
true causal effect.Whenoneormore invalid IVsarepresent (i.e., one
SNP has an effect on an outcome through a different pathway than
CRP), the IVWestimate deviates from the true causal effect.
MR-Egger
We used MR-Egger to account for potential unbalanced pleiotropy
in the multiple-variant instrument.34 When unbalanced pleiot-
ropy is present, an alternative effect (positive or negative) is pre-
sent between the SNP and the outcome, and it could bias the
estimate of the causal association. TheMR-Egger method is similar
to the IVW analysis but does not force the intercept to pass
through the origin. The slope of the MR-Egger regression provides
the estimate of the causal association betweenCRP and the clinical
outcome. An MR-Egger intercept that is significantly different
from 0 suggests directional pleiotropic effects that could bias un-
corrected estimates of the causal effect. MR-Egger regression de-
pends on the InSIDE (instrument strength independent of direct
effect) assumption, which states that the strengths of the effectThe Americanof the SNP on the outcome are uncorrelated with the direct pleio-
tropic effect of the SNP on the outcome.
Weighted Median and Penalized Weighted Median
Weapplied themedian-basedmethod toprovide robust estimates of
causal association even in the presence of horizontal pleiotropy
when up to 50% of the information contributed by the genetic var-
iants is invalid.35 In PWM analysis, the effect of each variant is
weightedbya factor that corresponds to theQstatistics (heterogene-
ity test) of the SNP; thismeans thatmostvariantswill notbe affected
by this correction, but the causal effect of the outlying variants,
which are most likely to be invalid IVs, will be down-weighted.
We displayed the individual SNP estimates of causal effect and
corresponding 95% confidence intervals (CIs) in a forest plot. To
assess whether one of the variants used in the genetic score had
disproportionate effects, we performed ‘‘leave-one-out’’ analyses,
where one SNP at a time is removed from the score. We depicted
the relationship between the SNP effect on CRP and the SNP effect
on the clinical outcomes in a scatterplot and plotted the individ-
ual SNP effect against the inverse of their standard error in a funnel
plot. When unbalanced pleiotropy is absent, the causal-effect esti-
mates of the individual should center around the meta-analysis
estimate in the funnel plot.
We used the proportion of CRP variance explained by the ge-
netic instruments (0.014 for the rs2794520 SNP and 0.065 for
the 52-SNP score) to perform power calculations for each outcome
by using the online tool mRnd.36 We calculated the power to
detect a relative 5%, 10%, 15%, and 20% difference in outcome
risk. For example, a 10% difference refers to an odds ratio (OR)
of at least 0.90 or 1.10 in outcome risk (Table S13).Results
HapMap GWAS Meta-analysis for Amounts of CRP
The HapMap meta-analysis identified 3,977 genome-wide-
significant variants at p < 5 3 108 (quantile-quantile
[Q-Q] plot, Figure S1; Manhattan plot, Figure S2), which
mapped to 48 distinct loci (Table 1; Table S3). Of the
previously reported 18 variants for CRP, 16 remained
associated. Compared with the variants in the previous
GWAS, the rs6901250 variant at the GPRC6A locus
(p ¼ 0.09) and the rs4705952 variants at the IRF1 locus
(p ¼ 2.7 3 103) were not significant. The b estimates
for natural-log-transformed CRP for each of the associated
loci ranged from 0.020 to 0.229. We observed the
strongest association for rs2794520 at CRP (b ¼ 0.182 in
the natural-log-transformed CRP [mg/L] per copy incre-
ment in the coded allele; p ¼ 4.17 3 10523), followed by
rs4420638 at APOC1 and APOE (b ¼ 0.229, p ¼ 1.23 3
10305). As in previous GWAS meta-analysis, the lead
variant within interleukin-6 receptor (IL6R) was rs4129267
(b ¼ 0.088; p ¼ 1.2 3 10129). We identified rs1880241
upstream of IL6 (b ¼ 0.028; p ¼ 8.4 3 1014), related to
the interleukin-6 pathway. In addition to the previously
described interleukin-1 signaling, the IL1RN-IL1F10 locus
(interleukin-1 receptor antagonist and interleukin-1 family
member 10), we found rs9284725 within interleukin-1 re-
ceptor 1 (IL1R1; b ¼ 0.02; p ¼ 7.3 3 1011; Table 1).
Compared with the overall meta-analysis including both
sexes, the sex-specific meta-analyses did not identifyJournal of Human Genetics 103, 691–706, November 1, 2018 697
Table 1. Newly Identified Loci Associated with CRP
Varianta Positionb
Coded
Allele
Frequency of
Coded Allele bc
Standard
Error p Value Closest Gened
1KG Lead
Variante
Loci Found in the HapMap GWAS
rs469772 chr1: 91,530,305 T 0.19 0.031 0.005 5.54 3 1012 ZNF644 rs469882
rs12995480 chr2: 629,881 T 0.17 0.031 0.005 1.24 3 1010 TMEM18 rs62105327
rs4246598 chr2: 88,438,050 A 0.46 0.022 0.004 5.11 3 1010 FABP1 –
rs9284725 chr2: 102,744,854 C 0.24 0.027 0.004 7.34 3 1011 IL1R1 rs1115282
rs1441169 chr2: 214,033,530 G 0.53 0.025 0.004 2.27 3 1011 IKZF2 –
rs2352975 chr3: 49,891,885 C 0.30 0.025 0.004 6.43 3 1010 TRAIP rs10049413
rs17658229 chr5: 172,191,052 C 0.05 0.056 0.010 5.50 3 109 DUSP1 rs34471628
rs9271608 chr6: 32,591,588 G 0.22 0.042 0.005 2.33 3 1017 HLA-DQA1 rs2647062
rs12202641 chr6: 116,314,634 T 0.39 0.023 0.004 3.00 3 1010 FRK –
rs1490384 chr6: 126,851,160 T 0.51 0.025 0.004 2.65 3 1012 C6orf173 rs1490384
rs9385532 chr6: 130,371,227 T 0.33 0.026 0.004 1.90 3 1011 L3MBTL3 –
rs1880241 chr7: 22,759,469 G 0.48 0.028 0.004 8.41 3 1014 IL6 rs13241897
rs2710804 chr7: 36,084,529 C 0.37 0.021 0.004 1.30 3 108 KIAA1706 –
rs2064009 chr8: 117,007,850 C 0.42 0.027 0.004 2.28 3 1014 TRPS1 rs6987444
rs2891677 chr8: 126,344,208 C 0.46 0.020 0.004 1.59 3 108 NSMCE2 rs10956251
rs643434 chr9: 136,142,355 A 0.37 0.023 0.004 1.02 3 109 ABO 9:136146061
rs1051338 chr10: 91,007,360 G 0.31 0.024 0.004 2.27 3 109 LIPA –
rs10832027 chr11: 13,357,183 G 0.33 0.026 0.004 4.43 3 1012 ARNTL rs10832027
rs10838687 chr11: 47,312,892 G 0.22 0.031 0.004 9.12 3 1013 MADD rs7125468
rs1582763 chr11: 60,021,948 A 0.37 0.022 0.004 2.37 3 109 MS4A4A rs1582763
rs7121935 chr11: 72,496,148 A 0.38 0.022 0.004 5.28 3 109 STARD10 –
rs11108056 chr11: 95,855,385 G 0.42 0.028 0.004 5.42 3 1014 METAP2 rs12813389
rs2239222 chr14: 73,011,885 G 0.36 0.035 0.004 9.87 3 1020 RGS6 rs2239222
rs4774590 chr15: 51,745,277 A 0.35 0.022 0.004 2.71 3 108 DMXL2 rs1189402
rs1558902 chr16: 53,803,574 A 0.41 0.034 0.004 5.20 3 1020 FTO rs55872725
rs178810 chr17: 16,097,430 T 0.56 0.020 0.004 2.95 3 108 NCOR1 –
rs10512597 chr17: 72,699,833 T 0.18 0.037 0.005 4.44 3 1014 CD300LF, RAB37 rs2384955
rs4092465 chr18: 55,080,437 A 0.35 0.027 0.004 3.11 3 1010 ONECUT2 –
rs12960928 chr18: 57,897,803 C 0.27 0.024 0.004 1.91 3 109 MC4R –
rs2315008 chr20: 62,343,956 T 0.31 0.023 0.004 5.36 3 1010 ZGPAT –
rs2836878 chr21: 40,465,534 G 0.27 0.043 0.004 7.71 3 1026 DSCR2 rs4817984
rs6001193 chr22: 39,074,737 G 0.35 0.028 0.004 6.53 3 1014 TOMM22 rs4821816
Additional Loci Found in the 1KG GWAS
rs75460349 chr1: 27,180,088 A 0.97 0.086 0.014 4.50 3 1010 ZDHHC18 –
rs1514895 chr3: 170,705,693 A 0.71 0.027 0.004 2.70 3 109 EIF5A2 –
rs112635299 chr14: 94,838,142 T 0.02 0.107 0.017 2.10 3 1010 SERPINA1, SERPINA2 –
rs1189402 chr15: 53,728,154 A 0.62 0.025 0.004 3.90 3 109 ONECUT1 –
Additional Loci Found in the BMI-Adjusted 1KG GWAS
3:47431869 chr3: 47,431,869 D 0.59 0.024 0.004 1.10 3 108 PTPN23 –
rs687339 chr3: 135,932,359 T 0.78 0.030 0.005 2.80 3 1010 MSL2 –
(Continued on next page)
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Table 1. Continued
Varianta Positionb
Coded
Allele
Frequency of
Coded Allele bc
Standard
Error p Value Closest Gened
1KG Lead
Variante
rs7795281 chr7: 74,122,854 A 0.76 0.028 0.005 3.10 3 108 GTF2I –
rs1736060 chr8: 11,664,738 T 0.60 0.029 0.004 2.60 3 1013 FDFT1 –
17:58001690 chr17: 58,001,690 D 0.44 0.026 0.004 9.50 3 1010 RPS6KB1 –
rs9611441 chr22: 41,339,367 C 0.49 0.022 0.004 1.40 3 108 XPNPEP3 –
aHapMap variants are presented, except for the 1KG additional findings.
bPositions are according to UCSC Genome Browser build hg19.
cb coefficients represent a 1-unit change in the natural-log-transformed CRP (mg/L) per copy increment in allele A1.
dThe closest gene represents either the gene in which the variant is located or the closest gene.
eFor HapMap loci, the lead variant from the 1KG GWAS is presented when the loci were also found in the 1KG GWAS.additional loci forCRP.However, at four genetic variants,we
found evidence for heterogeneity in effect estimates be-
tween women and men (Table S4), although the directions
of associations were consistent.
1KG GWAS Meta-analysis for Amounts of CRP
In the 1KG meta-analysis, 8,002 variants were associated
with CRP at p < 5 3 108 (Q-Q plot, Figure S3; Manhattan
plot, Figure S4). This resulted in 40 distinct loci, of which
36 overlapped the HapMap meta-analysis (Table 1). The
lead variant at the CRP locus in the 1KG GWAS was
rs4287174 (b ¼ 0.185; p ¼ 1.95 3 10398), which was
in high LD with rs2794520 (r2 ¼ 0.98), the lead variant
at the CRP locus in the HapMap GWAS. Among
eight of the overlapping loci (rs1260326, rs1490384,
rs10832027, rs1582763, rs7310409, rs2239222, rs340005,
and rs1800961), the lead variant was at the same position
in both GWASs. Compared with HapMap variants, the four
additional variants identified in 1KG were rs75460349,
rs1514895, rs112635299, and rs1189402. The variants
rs1514895 and rs1189402 were available in the HapMap
GWAS but were not associated at the genome-wide
threshold (p ¼ 1.2 3 107 and p ¼ 8.1 3 103, respec-
tively). The two variants rs75460349 and rs112635299
were not available in the HapMap GWAS or in high LD
(r2 < 0.8). rs75460349 is a low-frequency variant with a
coded allele frequency of 0.97 (b ¼ 0.086; p ¼ 4.5 3
1010). Also, rs112635299 near SERPINA1 and SERPINA2
is a low-frequency variant with a MAF of 0.02 (b ¼ 0.107;
p ¼ 2.1 3 1010). Adjustment for BMI in the 1KG GWAS
(n ¼ 147,827) revealed six additional loci that were not
associated with CRP in the HapMap or 1KG primary ana-
lyses (Table 1; Table S5; Q-Q plot, Figure S5; Manhattan
plot, Figure S6). The associations at three lead variants
were much reduced after adjustment for BMI (rs1558902
[FTO], padjusted ¼ 0.40; rs12995480 [TMEM18], padjusted ¼
0.02; rs64343 [ABO], padjusted ¼ 1.0 3 107). Both FTO
and TMEM18 are well-known obesity-related genes. Except
for the FTO, TMEM18, and ABO loci, all distinct loci iden-
tified in the primary 1KG analysis were also associated with
CRP in the BMI-adjusted 1KG analysis. No genome-wide-
significant association was observed on the X chromosome
in the 1KG GWAS, which included 102,086 individuals.The AmericanLD Score Regression
The HapMap GWAS LDSC intercept was 1.03 (standard
error¼ 0.013), and the 1KG intercept was 1.02 (standard er-
ror ¼ 0.011). This suggests that a small proportion of the
inflation is attributable to confounding bias (12% for
the HapMap GWAS and 13% for the 1KG GWAS). Hence,
the vast majority of inflation is due to the polygenic archi-
tecture of circulating amounts of CRP. As depicted in
Figure 1, CRP showed strong positive genetic correlations
with anthropometric traits (e.g., Rg ¼ 0.43 and p ¼ 5.4 3
1015 for BMI), glycemic phenotypes (e.g., Rg ¼ 0.33 and
p ¼ 3.1 3 106 for type 2 diabetes), lipid phenotypes (e.g.,
Rg ¼ 0.29 and p ¼ 7.9 3 105 for triglycerides), and CAD
(Rg ¼ 0.23 and p ¼ 2.4 3 105) (Table S6). By comparison,
CRP showed inverse genetic correlations with educational
attainment (e.g., Rg ¼0.27 and p ¼ 9.23 107 for college
completion), lung function (e.g., Rg ¼0.24 and p¼ 4.63
1012 for forced vital capacity), and high-density lipopro-
tein cholesterol (Rg ¼ 0.30 and p ¼ 4.8 3 109).
Additional Signals at Distinct Loci
Approximate conditional analyses in the 1KG GWAS re-
vealed additional signals at nine loci (Table S7). Five loci
showed one secondary signal (IL6R, NLRP3, HNF1A,
CD300LF, and APOE and APOC1), the PPP1R3B locus had
two additional signals, the LEPR locus had three additional
signals, and the SALL1 locus had four additional signals,
whereas the CRP locus showed a total of 13 distinct associ-
ated variants. Interestingly, the rs149520992 rare variant
(MAF ¼ 0.01) mapping to the CRP locus showed an associ-
ation at pconditional¼ 3.73 1015 with b ¼0.272 for the T
allele. The GCTA effect estimates for the ten distinct vari-
ants identified in the vicinity of CRP by the 1KG condi-
tional analysis are highly correlated with these variants’
effect estimates obtained from the RS-I andWGHS individ-
ual-level data (rRS ¼ 0.97 and rWGHS ¼ 0.84), confirming
the reliability of the GCTA estimates.
Explained CRP Variance
The lead variant at the CRP locus in both the HapMap
(rs2794520) and 1KG (rs4287174) GWASs explained
1.4% of the variance in natural-log-transformed CRP
amounts. The distinct CRP variants derived from the jointJournal of Human Genetics 103, 691–706, November 1, 2018 699
Figure 1. Genome-wide Genetic Correlation between Serum Amounts of CRP and Different Phenotypes and Clinical Diseases
The genetic correlation and its standard error are estimated by LDSC analysis. Abbreviations are as follows: ADHD, attention deficit and
hyperactivity disorder; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; HOMA-B, homeostatic model assessment b cell
function; HOMA-IR, homeostatic model assessment insulin resistance; and HbA1C, hemoglobin A1c.conditional analysis in the 1KG GWAS explained 4.3% of
the variance. The lead variants at all distinct loci together
explained 6.2% of the CRP variance in the HapMap
GWAS and 6.5% in the 1KG GWAS. When we added the
distinct variants derived from the conditional analysis at
associated loci, the variance explained by all associated
loci was 11.0% in the 1KG GWAS.
Functional Annotation
We applied DEPICT and MAGMA analyses for functional
annotation and biological interpretation of the findings.
The DEPICT analysis included 9,497 genome-wide-signifi-
cant variants covering 283 genes and prioritized 55 candi-
dategenesacross29regions (FDR<0.05;TableS8).Theprior-
itized genes included IL6R, which mapped to the 1q21.3
locus (represented by rs4129267), and APCS, whichmapped
to the 1q32.2 locus. Investigating 10,968 reconstituted gene
sets for enrichment, DEPICT highlighted 583 (5.3%) gene
sets to be significantly enriched among CRP-associated loci
at FDR< 0.05 (Table S9). Using further clustering, we identi-
fied 66 groups of gene sets that substantially correlated and
clustered in twosets, onemainlycomposedof immunepath-
ways and the other enriched with metabolic pathways
(Figure 2). In Figure 3, we present the prioritized genes and
themost significant gene sets.We found synovial fluid, liver
tissue, andmonocytes to be enrichedwith expression of the
prioritized genes (FDR< 0.05).We appliedMAGMAanalysis
to theHapMapGWAS, identifyingfivesignificantlyenriched
gene sets (Bonferroni-corrected p< 0.05; Table S10). Results
included consequences of EGF induction, positive regula-
tion of gene expression, and the interleukin-6 signaling
pathway, in line with the most strongly prioritized gene
from DEPICT gene prioritization. MAGMA analysis priori-
tized liver as a sole enriched tissue (p ¼ 0.048).700 The American Journal of Human Genetics 103, 691–706, NovemTo prioritize the most likely trait-relevant gene for each
GWAS locus, we interrogated the GWAS data with cis-
eQTL data identified from 44 post-mortem tissues and a
large whole-blood eQTL meta-analysis by using colocaliza-
tion analysis (Table S11). Figure S7 presents the GWAS loci
that colocalize with cis-eQTLs with the corresponding tis-
sue, the colocalizing gene, and the posterior probability
that one shared underlying variant drives both associations.
Out of the 58 lead gSNPs, 25 SNPs (43%) showed evidence
of colocalization with one or more local eQTL effects (pos-
terior probability > 0.9). For example, the rs2293476 locus
colocalized with several cis-eQTL effects for PABC4 and
pseudogenes OXCT2P1, RP11-69E11.4, and RP11-69E11.8.
The rs10925027 locus colocalized with the cis-eQTL effect
for NLRP3 exclusively in the highly powered blood meta-
analysis. Out of 25 loci, nine loci had only one colocalizing
gene. Altogether, gSNP-associated cis-eQTL effects were pre-
sent in up to 14 different tissues, of which whole blood,
esophagus mucosa, skin, and tibial nerve were the most
frequent.
Mendelian Randomization Analyses
We observed a protective effect of genetically determined
variance in CRP with schizophrenia with an IVW OR of
the 52-SNP score of 0.89 (95% CI ¼ 0.81–0.97; p ¼ 6.6 3
103; Tables S14 and S15; Figure S8–S11). The MR-Egger
intercept was compatible with no unbalanced pleiotropy
(p ¼ 0.48). The estimate of the rs2794520 variant was
comparable to the 52-SNP score estimate (OR ¼ 0.89;
95% CI ¼ 0.84–0.94; p ¼ 0.046). The WM and PWM esti-
mates were comparable to the IVW estimate (ORWM ¼
0.89 and PWM ¼ 5.1 3 103; ORPWM ¼ 0.89 and PPWM ¼
4.4 3 103). The ‘‘leave-one-out’’ analysis provided
evidence that no single variant was driving the IVWber 1, 2018
Figure 2. Results of the DEPICT Functional Annotation Analysis
Each node represents an exemplar gene set from affinity-propagation clustering, and links represent corresponding Pearson correlation
coefficients between individual enriched gene sets (only the links with r > 0.3 are shown). DEPICT GSE P refers to the gene-set enrich-
ment p value for that DEPICT gene-set generated by DEPICT. As an example, outlined are the individual gene sets inside two clusters
(‘‘inflammatory response’’ and ‘‘negative regulation of peptidase activity’’).point estimate (Figure S10). The causal OR between the
rs2794520 variant and BD was 1.33 (95% CI ¼ 1.03–1.73;
p ¼ 0.032). For the 52-SNP score, the IVW OR was 1.16
(95% CI ¼ 1.00–1.35; p ¼ 0.054). The MR-Egger intercept
was compatible with unbalanced pleiotropy (p ¼ 0.049).
The MR-Egger estimate OR of the 52-SNP score was
comparable to the rs2794520 estimate (OR ¼ 1.36; 95%
CI ¼ 1.10–1.69; p ¼ 6.7 3 103), as were the WM andThe AmericanPWM estimates (ORWM ¼ 1.33 and PWM ¼ 3.4 3 103;
ORPWM ¼ 1.32 and PPWM ¼ 4.3 3 103).
We observed evidence against a causal association be-
tween either CRP rs2794520 (OR ¼ 1.01; 95% CI ¼ 0.91–
1.12; p ¼ 0.88) or the 52-SNP instrument (OR ¼ 0.96;
95% CI ¼ 0.84–1.09; p ¼ 0.51) and CAD. An Egger inter-
cept of 0.014 suggested the presence of unbalanced pleiot-
ropy (p ¼ 5.8 3 103), and the MR-Egger causal estimateJournal of Human Genetics 103, 691–706, November 1, 2018 701
Figure 3. Heatmap Representing the Results of DEPICT Functional Annotation Analysis
Each row represents enriched (FDR< 0.05) gene sets, and each column represents prioritized (FDR< 0.05) genes. Colors on the heatmap
represent each gene’s contribution to gene-set enrichment (GSE; depicted as a Z score; only the top ten highest Z scores per gene set are
visualized). Sidebars represent p values for GWAS, GSE, and gene prioritization (nominal p value on log10 scale). The top ten gene sets per
annotation category are visualized. Abbreviations are as follows: GO, GeneOntology; KE, Kyoto Encyclopedia of Gene andGenomes; RE,
REACTOME pathways; MP, mouse phenotype; and PI, protein-protein interaction.was OR ¼ 0.79 (95% CI ¼ 0.67–0.94; p ¼ 0.012). However,
the WM and PWM showed no association between CRP
and CAD. For AD, there was evidence against an associa-
tion with rs2794520 (p ¼ 0.592), although the IVW OR
showed a protective effect (OR ¼ 0.51; 95% CI ¼ 0.30–
0.88; p ¼ 0.015). The Egger intercept of 0.046 suggested
unbalanced pleiotropy (p ¼ 0.042), and the MR-Egger OR
was 0.27 (95% CI ¼ 0.12–0.60). However, the association
was null for the WM and PWM analyses (ORWM ¼ 1.04
and PWM ¼ 0.61; ORPWM ¼ 1.05 and PPWM ¼ 0.53). We
observed evidence against an effect for CD, DBP, IBD, RA,
and SBP for the rs2794520 variant and the IVW, MR-Egger,
WM, and PWM analyses.Discussion
Using genomic data from >200,000 individuals, we have
identified 58 distinct signals for circulating amounts of
CRP, confirming 16 previously identified CRP loci. BMI-
adjusted GWASs suggested that the vast majority of702 The American Journal of Human Genetics 103, 691–706, Novemgenetic risk variants affect CRP amounts independently of
its main determinant (BMI). The genome-wide in silico func-
tional annotation analysis highlights 55 genes that are
likely to explain the association between 29 signals and
amounts of CRP. The data identified gene sets involved in
the biology of the immune system and liver as main regula-
tors of serum amounts of CRP.MR analyses supported causal
associations between genetically increased CRP and a pro-
tective effect on schizophrenia and increased risk of BD.
Obesity is one of the main determinants of chronic low-
grade inflammation in the general population.37,38 Adjust-
ment for BMI in the CRP GWAS abolished the association
at only three lead variants, suggesting that the genetic
regulation of chronic low-grade inflammation is largely in-
dependent of BMI. Notably, BMI adjustment resulted in
the identification of six variants that were not associated
with CRP in the BMI-unadjusted GWAS. This supports
the notion that adjustment for covariates that explain
phenotypic variance could improve the statistical power
in linear model analyses of quantitative traits.39 Although
adjustment for heritable correlated traits in GWASs couldber 1, 2018
bias effect estimates (collider bias),40 there is consistent ev-
idence in the literature that BMI has a causal direct effect
on CRP amounts,41 and therefore, collider bias in CRP
GWASs adjusted for BMI is less likely.
The sex-stratified analyses revealed significant heteroge-
neity in effect estimates between men and women at only
four lead variants, which represent fewer than 10% of all
CRP loci. Even among these four loci, the effect directions
were similar; thus, the heterogeneity was limited to effect
sizes. The data suggest that the difference between men
andwomen in amounts of CRP is less likely to be explained
by genetic factors. Furthermore, two signals identified in
the former HapMap GWAS of CRP amounts were not sig-
nificant in the current HapMap GWAS. The effect esti-
mates in the current analyses were too small to identify
with our sample size.
The top variant at the CRP locus in both the HapMap
and 1KG GWASs explained 1.4% of the variance in circu-
lating amounts of CRP. The approximate conditional anal-
ysis resulted in 13 variants jointly associated within the
CRP locus in the 1KG GWAS. With respect to locus defini-
tion, we used a more conservative distance criterion than
other GWASs, which often use 5500 kb surrounding the
GWAS peak.42 Here, we used the criterion that the mini-
mum distance between the boundaries of loci is 500 kb.
In order to identify further variants associated with
amounts of CRP, we performed approximate conditional
analyses, which resulted in multiple putative additional
variants also inside and near genes that were not identified
in the primary GWAS. As an example, the CRP locus
spanned >2 Mb according to our criterion. Approximate
conditional analysis revealed that two variants, namely
rs3027012 near DARC and rs56288844 near FCER1A,
both downstream of CRP, were associated with CRP
amounts. Furthermore, upstream of CRP, we identified a
variant near FCGR2A (immunoglobulin G Fc receptor II).
These results show that for a given lead variant, potentially
multiple causal loci—here DARC, FCER1A, and FCGRA2
alongside CRP—contribute to chronic low-grade inflam-
mation and variation in circulating amounts of CRP.
DEPICT analysis provided further evidence that the
genes annotated to the associated CRP variants mainly
cluster in the immune and liver biological systems.
Notably, the gene set ‘‘inflammatory response,’’ which cap-
tures both immune response and liver metabolism, was the
main connector network between the two networks. This
is in line with the observation that CRP is mainly produced
by liver cells in response to inflammatory cytokines during
acute and chronic inflammation.43 Interestingly, the anal-
ysis highlighted iron homeostasis as an enriched gene set.
In agreement, the conditional analysis highlighted a
distinct genetic association at the hemochromatosis gene
HFE, encoding a transmembrane protein of the major his-
tocompatibility complex (MHC) class I family. Previous
studies have shown that iron metabolism plays a pivotal
role in inflammation.44,45 However, genetic pleiotropy
could highlight co-regulated pathway-analysis networksThe Americanthat do not cause inflammation per se. It is also important
to note that the results of DEPICT analyses apply to recon-
stituted gene sets that might sometimes have slightly
different overlaying biological themes than the original
gene-set annotation.
The MR analyses validate previous evidence that
genetically elevated CRP is protective for the risk of schizo-
phrenia,13,46 although observational data suggest a posi-
tive association between CRP and risk of schizophrenia.47
For BD, we observed a positive causal effect, which is in
line with previous MR and observational studies.13,48
Although the causal underlying mechanisms remain to
be elucidated, a hypothesis for the schizophrenia observa-
tion might be the immune response to infections early in
life. Amounts of acute-phase response proteins in dry
blood spots collected at birth are lower for individuals
with non-affective psychosis, which includes schizo-
phrenia, than for control individuals, suggesting a weaker
immune response at birth.49 Also, neonates who have been
exposed to a maternal infection and have low amounts of
acute-phase response proteins have a higher risk of
schizophrenia.50 Altogether, the evidence suggests that a
deficient immune response could contribute to chronic
infection in children and the development of schizo-
phrenia. For AD and CAD, the Egger intercept showed ev-
idence of unbalanced pleiotropy, and the Egger estimate
showed a protective effect of CRP on the risk of AD and
CAD. However, for both outcomes, the effects of the WM
and PWM analyses, as well as analyses using the single
rs2794520 variant (which is least likely to be affected by
pleiotropy), were null. The MR-Egger estimate relies on
the InSIDE assumption, which states that the strength of
the association between the genetic variants and CRP is in-
dependent of the strength of the direct pleiotropic effects
of the genetic variants on the outcome. This assumption
can be violated when the genetic variants are associated
with a confounder of the CRP-outcome association. Such
a scenario can occur when the genetic variants are associ-
ated with an exposure that is causally upstream of the
exposure under study. In the context of the association
between CRP and either AD or CAD, this could be
lipids or glycemic phenotypes. Several genetic variants
used in the 52-SNP instrument are associated with meta-
bolic phenotypes that might affect amounts of CRP. In
agreement, the WM and PWM, in which the InSIDE
assumption is relaxed, and the single-variant analysis
showed no association. Furthermore, the observation
that CRP is not causally related to CAD in the MR analyses
is comparable to the findings of previous published
studies.51 Power calculation showed that we had 100%
power to detect a 10% difference in CAD risk, so the prob-
ability of a false-negative finding is small. Also, CRP is
associated with future CAD in observational studies, and
randomized trials have shown a beneficial effect of
lowering inflammation with the use of statins52 and cana-
kinumab53 on CAD risk, but this effect is unlikely to be
attributable to CRP.Journal of Human Genetics 103, 691–706, November 1, 2018 703
The strengths of our study are the use of a very large sam-
ple size for CRP and the use of both HapMap and 1KG
imputed data. Furthermore, we conducted sex-specific
and BMI-adjusted analyses to study the effect of sex and
body mass on the associations between genetic variants
and CRP. To maximize power and to efficiently use the
data, we meta-analyzed all available samples in a discovery
setting without replication. The consistent association of
the variants in >50 studies at a strict Bonferroni-corrected
threshold provide confidence that our findings represent
true associations.We used both HapMap and 1KG imputed
data to identify genetic variants for circulating amounts of
CRP. At the start of the project, more studies had HapMap
imputed data available. Hence, the sample size and thus po-
wer in theHapMapGWASwas higher than that in the 1KG.
Also, HapMap could have identified variants that were not
identified by the 1KG GWAS.54 Nevertheless, 1KG offers
better coverage of uncommon variants and includes indels,
which are not included in the HapMap reference panel.
Including both reference panels, we used all available sam-
ples and maximized the possibility of identifying both
common and uncommon genetic variants for CRP.
However, we note limitations to our study. GWASs
merely identify loci associated with complex phenotypes,
and the identification of causal genes remains challenging.
We included only individuals of European ancestry;
the generalizability of our findings to other races and eth-
nicities is uncertain. In addition, although our analyses
provide support for causal associations, we acknowledge
that we might not have identified the causal variants,
and we might not have eliminated residual confounding.
The colocalization analyses provide evidence for colocali-
zation of CRP GWAS signals and eQTLs; however, they
do not provide evidence that the GWAS signal functions
on CRP through gene expression. We further note that
the method assumes identical LD structure from the
GWAS and eQTL datasets. Given that non-European sam-
ples make up 14% of the full dataset, this assumption
might be violated for some tissues. Last, we meta-analyzed
all available samples in one meta-analysis and did not
replicate our findings in an independent sample. There-
fore, our findings might need replication.
In conclusion, we performed a large GWASmeta-analysis
to identify genetic loci associated with circulating amounts
of CRP, a sensitive marker of chronic low-grade inflamma-
tion, and found support for a causal relationship between
CRP and decreased risk of schizophrenia and increased
risk of BD. Given that inflammation is implicated in the
pathogenesis of multiple complex diseases, our insights
into the biology of inflammation could contribute to
future therapies and interventions.Accession Numbers
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